Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B. Riley Securities analyst Madison El-Saadi initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and a...
Wells Fargo analyst Benjamin Burnett assumes Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announces Price ...
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.
B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target ...
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price targe...
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.
